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Somatic Cell Gene Mutations in Humans:
Biomarkers for Genotoxicity
by Richard J. Albertini, Janice A. Nicklas,1 and
J. Patrick O'Neill'
Somatic cell gene mutations arising in vivo in humans provide biomarkers for genotoxicity. Four assays,
each measuring changes in a different "recorder" gene, are available for detecting mutations of the
hemoglobin (Hb) and glycophorin A (gpa) genes in red blood cells and the hypoxanthine-guanine phos-
phoribosyltransferase (hprt) and HLA genes in T-lymphocytes. Mean adult background mutant frequencies
have been established;i.e., approximately 4 x 108(Hb), 5-10 x 10-6 (hprt), 10-20 x 10-6(gpa) and30 x 10-6
(HLA). All the assays have now been used in studies of individuals exposed to physical and/or chemical
genotoxic agents, andall have shown elevatedvalues following exposures; examples arepresented. In addition
to quantitation, the lymphocyte assays allow molecular analyses of in vivo mutations, the definition of
background and induced mutational spectra, and the search for unique changes for characterizing specific
mutagens. The HPRT system currently has the largest database in this regard. Approximately 15% of adult
background hprt mutations are due to gross structural alterations (primarily deletions) having random
breakpoints; 85% result from "point" changes detected only by sequencing. In contrast, a specific intragenic
deletion due to DNA cleavage at specific sites characterizes fetal hprt mutations, implicating a developmental
mistake in their genesis. (This kind of developmental mistake in other genes is frequently observed in
lymphoid malignancies.) Mutational spectra arejust beginning to be defined for inducedhprt mutations, e.g.,
ionizing radiation produces large deletions. Characterization of HLA mutations at the molecular level,
accomplished thus far at the level of Southern blots, shows that approximately 30% result from events that
render the gene "homozygous," i.e., somatic recombination. Details of the molecular aspects ofin vivo gene
mutations in human lymphocytes are described.
Introduction
Environmental mutagens can produce disease in indi-
viduals by "inducing" lesions in critical genes of somatic
cells. Ifthe genes are important in malignant transforma-
tion,thediseaseis cancer. Otherdiseases mayalsohave an
environmental basis. Measures ofinduced or spontaneous
genetic damage arising in vivo in human somatic cells
havepublichealthrelevance asearlywarningdetectorsfor
such exposures.
Environmentally induced lesions in cells may be man-
ifestat anyleveloforganization ofthegeneticmaterial,i.e.,
the chromosome, the gene, or the primary DNA level.
Assays are available forquantifying and characterizing all
suchdamage.Atthe chromosome level, technical advances
inrecent years haveincreased therapidityandprecisionof
measures of aberrations and micronuclei. For primary
DNA lesions, there is a variety ofmethods for measuring
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chemical adducts, other lesions, or cellular repair
responses that reflect such lesions (1).
Genetic lesions in somatic cells are processed, resulting
in misinformation (or no information) encoded by the
involvedregionofDNA.Broadlyspeaking, suchprocessed
lesions are called "mutations." Chromosome-level genetic
damagemayresultinamutationifitis notlethaltothecell
and disrupts or deletes a gene or its controlling elements.
Similarly, primary DNA lesions, while not themselves
mutations, maybe processed to produce changes in soma-
tic genetic coding sequences. The final common pathway
for somatic genetic damage to be offunctional (i.e., patho-
genic) significance is aheritable alterationingeneticinfor-
mation, i.e., a somatic gene mutation. Measures ofsomatic
mutations are relevant for human population monitoring
because they measure this common functional pathway.
When these mutations occur in critical regions, they pro-
duce genotoxic disease.
Most studies of human genotoxic diseases are con-
cerned with genes involved in the disorder. Cancer
research has become highly focused on the critical genes
involvedinmalignanttransformation. Certainly, studiesof
specific oncogenes and tumor-suppressor genes are indis-ALBERTINI ET AL.
pensable for an understanding of pathogenesis, i.e., for
relating gene malfunctions to disease states. However,
geneticlesions arisingincancer-associated genesarerare,
usually nonselectable, and, when they do arise, may alter
cell proliferation characteristics such that their primary
frequencies become difficult to measure. For investiga-
tions of the mutation process itself and for monitoring
human exposures to environmental mutagens, recourse is
made to somatic mutations in simple "housekeeping" or
other genes that result in easily recognized cellular phe-
notypic changes. Such somatic mutations serve as
recorders. Ofcourse,ultimately, correlationsmustbemade
between mutations in recorder genes and genotoxic dis-
eases in monitored populations for the former to have
validity for human risk assessment.
Thisreviewbrieflyconsiders andcompares allcurrently
available assays for measuring in vivo somatic cell gene
mutations in humans. Special emphasis is given to
hypoxanthine-guanine phosphoribosyltransferase (hprt)
mutations inT-lymphocytes forthreereasons: itisusedby
several laboratories, it has the largest current database,
and information is available regarding molecular charac-
terizations ofthe mutations arising in vivo.
Assays for Somatic Cell Mutations
Arising in Vivo in Humans
There currently are four assays for detecting in vivo
somatic cell gene mutations in humans. All measure
altered cellular phenotypes. For obvious reasons, the cur-
rentassays studymutations inblood cells; twoinredblood
cells (RBCs) and two in T-lymphocytes.
Somatic Mutations in Red Blood Cells
Somaticmutations ofthehemoglobin (Hb)genesandthe
glycophorin-A (gpa) gene are reflected as altered phe-
notypes in RBCs. Although the concept ofmonitoring in
vivo somatic mutations by studying changes in Hb came
first, an automated assayforactuallyscoringmutantswas
only recently developed (2,3). By far, most studies of in
vivo mutations detected as RBC changes have used the
GPA assay.
Since mature RBCs in mammals do not have a nucleus,
the mutations that produce phenotypic alterations must
arise at an earlier stage ofdifferentiation, i.e., in nucleated
bone marrow progenitor cells. Genotoxicants must reach
this body compartment to exert their effects. Bone mar-
row derived mutants are then amplified and recognized as
RBCs in peripheral blood. This relationship between
mutational events and mutant frequencies must be under-
stood to interpret mutagenicity studies using this assay.
At least some of the mutations induced in bone marrow
precursor cells will arise in multipotent stem cells that
produce cells that begin the differentiation process and
cellsthatrenewthestem-cell compartment. Because ofthe
latter, mutations occurring in multipotent cells are
reflected as mutants throughout the life ofthe individual,
i.e., have "longmemory." (Those arisingin more differenti-
ated cellswilleventuallydieout.)Thislongmemorymayor
may not be an advantage, depending on whether monitor-
ingis forgenotoxic exposures inthe recent ordistantpast.
A further consequence ofRBCs not having a nucleus is
that there is no possibility for molecular studies. There-
fore, indirect methods must be used to verify the muta-
tional basis of the phenotypic changes and molecular
mutational spectra cannot be determined. RBCs with
altered phenotypes are often referred to as "variants."
At present, mutation ofHb genes is determined only as
the specific mutations ofthewild-typeHb3 gene (HbA) to
three mutant Hb forms, i.e., HbS, Hb San Jose, and Hb
Leiden. The HbI gene is on chromosome llp and spans 2
kb (4,5). However, the specific mutations are much more
restricted changes, i.e., either specific base changes,
frameshifts, or small deletions. This gives a relatively
small target for mutation, as reflected in the low back-
ground variant frequencies in normal adults, i.e., 5-
10 x 10-8. Rare RBCs containing mutant Hb in the het-
erozygous state in HbA/HbA individuals are detected by
automated image analysis of cells fLxed on slides and
treated with fluorescent antimutant Hb polyclonal anti-
bodies (6).
Glycophorin A is the cell surface protein on RBCs that
defines the M and N blood group antigens. The M and N
groups differbytwo nonadjacent amino acids, are codomi-
nantly expressed on RBCs, and are specified by the only
two alleles at the gpa locus (7). The gpa mutants are
recognized onrare RBCs ofan M/N constitutional hetero-
zygote as either the simple loss of M or N expression or
loss ofexpression ofone (M or N), with double expression
of the other. Although the system has the disadvantage
that only M/N heterozygous individuals are informative,
the M and N gene frequencies are approximately equal in
all populations so that heterozygotes are approximately
50%ofallindividuals. ThesimplelossofM orNexpression
(called "hemizygous" mutation) is thought to arise from
allele inactivation somaticmutation (e.g., pointmutation or
deletion),whereas loss ofonewith doubleexpression ofthe
other (called "homozygous" mutation-not be confused
with constitutional homozygote) is believed to represent
somatic recombination, gene conversion, or chromosome
loss with duplication. The gpa locus is on chromosome 4q,
spans 44 kb and has 4 exons (8). It is a large target for
mutation, as reflected in background mutant frequencies
in normal adults, which are of the order of 10-20 x 10-6
forboth hemizygous and homozygous mutants. Thesegpa
mutants (variants) are enumerated by the use of a flow
cytometer with RBCs that have been treated with highly
specific anti-M and anti-N antibodies linked to green and
red fluorophors, respectively (9,10).
The RBC assays have several advantages for human
population monitoring. Because RBCs are so abundant in
blood, relatively small samples sufficeforanalysis. The Hb
assay measures precise gene alterations, making it vir-
tually impossible for nongenetic phenotypic changes
("phenocopies") to produce the variant cells scored as
mutants. However, the precise nature of these requisite
mutations is a difficulty, i.e., mutantfrequencies are so low
that large numbers of cells must be scored to achieve
statisticalreliability, and sometypes ofgenetic changewill
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not be detected. The former problem may be partially
overcome by mixing several antimutant Hb antibodies
when treating fixed cells, thereby measuring several dif-
ferentHboImutations simultaneously. The use ofanimage
analyzer greatly enhances the utility of this assay. The
GPA assayhas several advantages forhumanmonitoring.
It is extremely rapid, allowing for large numbers ofindi-
viduals to be easily studied. Also, it allows forrecognition
of potentially important genetic lesions such as somatic
recombination because ofthe autosomal location andlarge
target characteristics ofthe gene.
Somatic Mutations in T-Lymphocytes
Somatic mutations arising invivo in the hprt gene orin
oneormoreofthe HLAgenes canberecognizedinhuman
T-lymphocytes. A short-term assay for quantitating the
former was described almost 15 years ago, and a cloning
assayfor hprt mutations became available almost10years
ago (11-13). Several groups now use one or the other of
these assays forhuman studies (14,15). Acloningassayfor
studyingHLAmutations arisinginvivoinT-lymphocytes
was described almost 5 years ago (16).
One advantage of T-lymphocytes for in vivo muta-
genicity studies is that,when the cloning assayisused, in
vivo-derived mutants canbeisolated, propagated invitro,
and the mutation characterized at the molecular level. A
large database containing such information is developing
forhprtmutationswherethebackgroundmolecularmuta-
tional spectruminnonmutagenicindividualsisbeingchar-
acterized for comparison with spectra observed after
various environmental exposures (17). The hope is that
mutagens or classes ofmutagens will produce sufficiently
characteristic spectra of hprt damage to serve as signa-
tures for that specific exposure. If this hope is realized,
qualitative studies of in vivo somatic mutations may be
more informative than quantitative studies.
The T-lymphocyte population in vivo has enormous
heterogeneity. At the extreme, this population consists of
millions ofindividual in vivo clones, each identified by the
specific T-cell receptor (TcR) used by all members ofthat
clone. Specific T-cell receptors are dimeric cell-surface
proteins through which individual T-cells recognize for-
eign antigen. SpecificT-cellreceptors arespecifiedbyTcR
genesthatthemselvesundergo somaticdiversiflcationbya
process ofrearrangementofsegmentsofgerm-line genes.
The TcR rearrangement pattern of a given clone, fixed
during thymic differentiation, persists throughout the life
of the individual. Each of the millions of individual TcR-
defined T-cell clones is thereby characterized by a specific
and identifiable rearrangement of TcR genes. This can be
usedtoadvantageinthatmolecularanalyses ofTcRgenes
inT-cell mutants(selected onthebasis oftheirmutationof
some other gene, e.g., hprt or HLA) defines the random-
ness of the somatic mutation process or, conversely, its
clonality, i.e., tendency to occur in a nonrandom manner
among clones. Thus, the clonal distribution of somatic
mutation can be established (18).
As for RBCs, the in vivo kinetics ofT-cells make inter-
pretating mutation studies complex. T-lymphocytes arise
in the bone marrow, undergo maturation (rearrangement
ofTcRgenes)inthethymus, andthenhaveaprolongedlife
span inperipheral tissue, e.g., inlymph nodes, spleen, gut.
Theytravelfromsitetositeviatheblood.Thistrafficfrom
bonemarrowtothymustoperipheryispronouncedduring
fetal life and early childhood, becomes less pronounced
withage,andmayterminateinlateadolescence.Thereare
few or no stem cells as such in the adult; the long-lived
T-cells in the periphery maintain the T-lymphocyte popu-
lation, and there is no further addition to clonal diversity.
Most T-cells in the periphery at any given time are quies-
cent, i.e., intheGophase ofthe cell cycle, but areintermit-
tently stimulated to undergo cell division and clonal
amplification, usually by antigen.
Somatic mutations in T-lymphocytes may occur at sev-
eral differentiation stages in the fetus and children, but
probably can arise only in the periphery (i.e., in mature
T-cells) inadults. BecauseperipheralT-cells arepresentin
virtuallyallbodycompartments, mutagens canexerttheir
effects on these cells without having to reach the bone
marrowcompartment. Mutations arisingintheperiphery,
however, do not have longmemory, and T-cell mutations in
adultswillprobablyproduce transientincreases in invivo
mutant frequencies. This is advantageous or disadvan-
tageous, depending on the purpose ofthe study.
The hprt gene is on the X-chromosome (19). Thus, it is
hemizygous, either actually (males) or functionally
(females). The hprt gene is a constitutive but dispensable
housekeepinggene that codes for an enzyme (HPRT) that
phosphoribosylates hypoxanthine and guanine for purine
salvage. HPRT activity is also able to phosphoribosylate
purine analogues, e.g., 6-thioguanine (TG), to renderthem
cytotoxic. Inactivating mutations of the hprt gene allow
themutantcells to growinthepresenceofotherwisetoxic
concentrations ofpurineanalogues,providingaconvenient
means for selection. The X-chromosomal location of the
hprt gene is advantageous in obviating dominance-
recessive considerations, but disadvantageous in that
importantgenotoxic events such as somaticrecombination
cannot be detec-ted. The hprt gene spans 44 kb and
includes nine exons, makingit a large target for mutation
as reflected in background adult mutant frequencyvalues
that average 5-10 x 10-6 (20).
Two classes of assays are available for quantitating in
vivohprtmutations. Oneinvolves ashort-termassayusing
autoradiographyorimmunofluorescence todetect3H [thy-
midine] or bromodeoxyuridine (BrdU) incorporation,
respectively, in mutant (variant) cells that are resistant to
TG inhibition of first-round phytohemagglutinin (PHA)-
stimulated DNA synthesis in vitro (11,21). These short
term assays are simple, relatively inexpensive, and have
the potential for automation.
The second assay for hprt mutant T-cells uses direct
cloning. T-cells are cultured in limiting dilutions in the
presence and absence ofTG selection (12,13). The ratio of
cloningefficiencywith TG to cloningefficiencywithoutTG
defines the hprt mutant frequency. As noted, mutant
colonies canbeisolated andpropagatedinvitroforfurther
analysis. The HPRTcloningassayquantitativeresults are
quitesimilartothoseobtainedwiththe short-termassays.
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The HLA gene complex includes several linked loci
containing two classes of genes that encode tissue anti-
gens, which are cell-surface recognition molecules of
importance in immune responses. There are many alleles
at each of the HLA loci, resulting in marked population
polymorphism. Mutational loss of an antigen specified by
one allele at each of these loci can be easily detected in
constitutionally heterozygous individuals. The HLA gene
complex is on chromosome 6p. Its autosomal location
allows it to recognize potentially important genotoxic
events such as gene conversion and somatic recombination.
Thus far, onlymutations in two alleles of one class ofHLA
genes have been studied, i.e., HLA-A2 and HLA-A3. This
HLA gene spans 5 kb and contains 7 exons, making it
anotherlargetargetformutation. Invivomutantfrequen-
cies average approximately 20-30 x 10-6 for normal
adults (16).
An assayfor invivo-derived HLAloss mutants involves
direct cloning, as described for hprt mutations. However,
rather than selecting with TG, T-lymphocytes are first
treated with the appropriate anti-HLAantibody and com-
plement to kill nonmutant cells. Care must be taken that
immunoselection is complete. Calculations for mutant fre-
quencies are analogous to those for determining hprt
mutant frequencies. HLA mutant T-cells can be isolated,
propagated, and characterized.
Quantitative Assessment of in Vivo
Somatic Mutations in Humans
Therehave nowbeensufficientquantitativestudies ofin
vivo somaticmutations in humansusing one or more ofthe
assays described to permit a comparison ofresults.
Background (Spontaneous) Variant/Mutant
Frequencies
Several studies have defined background (spontaneous)
variant/mutant frequencies in nonexposed normal indi-
viduals,theeffectsofageand smokingintheseindividuals,
and variant/mutant frequency values in individuals with
cancer-prone conditions thought to be due to DNA repair
deficiencies. A summary of these quantitative results is
given in Table 1. Background variant/mutant frequency
values usingthe several assays reflect, in general, the size
ofthe genetic target and, perhaps, the kinds ofmutational
events that are scored by that assay. Therefore, back-
ground variant frequencies at the HbI3 locus reflect spe-
cific mutations in codons, i.e., a single transversion for
HbS, asingletransitionforHbSanJose, or aspecificsmall
deletion for Hb Leiden. The mean Hb variant frequency
for normal adults is 1-5 x 10-8/specific mutation (6).
Background variant frequencies at the gpa locus reflect a
Table 1. Comparative results ofvariant/mutant frequencies for the different in in vivo somatic cell gene mutation assays in adult humans
(unexposed).
RBC assays T-lymphocyte assays
hprt
Hb gpa Short term Cloning HLA
Normals
Mean background 1-5 x 10 (6) 10 x 10 5-10 x 10 -; 5-10 x 10'6 (17) 30 x 10 " (16,26)
values hemizygous (21,23-25)
10 x 10-6
homozygous (22)
Age effect NT T 2%/year (9,27) T 5%/year (25) 1 1.6-5%/year T (26)
(28-31)
Smoking effect* - (31) T 30% (32) T (25,33) 1 56% (28,31) NT
DNA repair defects (constitutional homozygotes)
Ataxia - (31) lb (34) NT T (35) NT
telangiectasia
Xeroderma - (31) -(22) NT 1 (36) NT
pigmentosum
Bloom syndrome NT 1 (37) 1 (38) NT NT
Fanconi anemia NT NT 1 (39) T (39) NT
Werner syndrome NT NT T (40) NT NT
Abbreviations: RBC, red blood cells; Hb, hemoglobin; GPA, glycophorin-A; HPRT, hypoxanthine-guanine phosphoribosyltransferase; C, variant/
mutant frequency increase; NT, not tested; -, no change.
aRate per codon in Hb,B gene: transversion for HbS, transition for Hb San Jose, and deletion for Hb Leiden.
*Not statistically significant in all studies.
b'Increase was primarily in hemizygous mutants.
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variety ofinactivating mutations giving hemizygous vari-
ants and events akin to somatic mutation giving homo-
zygous variants (22). The background mean frequency of
each ofthese is approximately 10 x 10-6, i.e., more than
two orders of magnitude greater that for Hb variants.
Mean hprt variant (short-term assay) and hprt mutant
(cloning assay) frequencies have been established for nor-
malnonmutagen-exposedadults. These areapproximately
the same, i.e., 5-10 x 10-6, as might be expected since
they each measure in vivo mutation of the same gene,
which is large target (17,21,23-25). Some genetic events
however(e.g.,somaticrecombination), arenotdetectableat
hprt. Finally, the mean background mutant frequency at
HLAis approximately30 x 10-6,which reflects thelarge
target size and the ability to record somatic exchanges
(16,26). The relative order of mean background variant/
mutantfrequenciesfornormaladultsis Hb < hprt <gpa <
HLA.
Superimposed on these mean background frequencies
maybe age effects and smokingeffects. Although, strictly
speaking, smoking is a mutagen exposure, it is so ubiq-
uitous that it must be accounted for in human population
monitoring. Anincrease invariant/mutant frequencywith
agehasbeenfoundforallassaystested(9,25-31).Smoking
has been found to increase mean gpa variant and hprt
variant and mutant frequency values (25,28,31-33). The
magnitude of increase, however, varied from study to
study and did not always reach statistical significance.
There is no report of this having been tested for HLA
mutations, and therewas no smokingrelated increase in a
small study ofHb somatic mutations.
Studies ofin vivo somatic mutations in individualswith
DNAdeficiencies have beenparticularlyinteresting. Both
gpavariant and hprt mutant frequencies are increased in
patients with ataxia telangiectasia [AT (34,35)]. The
increase for gpa is primarily for hemizygous variants.
There was no increase in Hb variant frequencies in AT
patients (31). Forxerodermapigmentosum(XP),therewas
noincreaseinvariantfrequencyforeitherHborgpa,buta
clearincreaseinmutantfrequencyforhprt (22,31,36). Itis
tempting to think that this reflects the necessity of the
mutagenreachingthebone marrowcompartments forthe
production ofRBC precursor mutations, and the abilityof
lymphocytes to circulate through skin and be subject to
UVeffects. HLAmutantfrequencies have notbeen deter-
mined in XP patients. For Bloom syndrome, both gpa and
hprt variant frequencies were increased, with no muta-
genicity studies reported for the other assays (37,38).
Unlike in AT, however, both hemizygous and homozygous
gpa variant frequencies were increased in Bloom syn-
drome, perhaps reflecting the marked chromosome level
changes seen in the disorder. Asingle study has reported
increased hprt variant and mutant frequencies in some
patients with Fanconi anemia and another an increase in
hprt variant frequency in individuals with Werner syn-
drome (39,40). In all ofthe DNA repair deficiency condi-
tions tested, the constitutional heterozygotes had, on
average, normal background variant/mutant frequency
values.
InducedVariant/Mutant Frequencies
Several studies have investigated the effects of expo-
sures to genotoxic agents in adult humans. These include
ionizing irradiations (Table 2) and several chemical
agents (Table 3).
Exposure to external beam ionizing irradiation results
in increases in hprt mutant frequencies in both radi-
otherapy technicians and patients, but not in increases in
gpa variant frequencies (32,33,41-44). Atomic bomb sur-
vivors studied45yearsafterexposure showedincreasesin
both hprt mutant and gpa variant frequencies (15,45-47).
Both showed a dose-response relationship with exposure
level and the slope was higher for the gpa response. This
latter difference may reflect the different sites of muta-
tions in RBCs and T-lymphocytes, and the potential long
life of RBC stem-cell mutants. However, the increased
frequencyofhprt mutants also demonstrates the longlife
of some mutant T-cells in vivo. An increase in the fre-
quencyofHb,gpa, and hprtvariants hasbeenreported in
individuals exposed to radiation as a result of accidental
environmental contamination (6,24,48-50).
Internal exposure to technetium-99m through radi-
onuclide angiography has yielded conflicting results in
studies ofhprt mutant frequency (51,52). However, inter-
nal exposure to yttrium-90 or iodine-131 through a radi-
oimmunotherapy (RIT) procedure clearly resulted in
increases in the hprt mutant frequency, which correlated
withtheinitialdosesofadministeredradioactivity(53,54).
(A specific spectrum of mutations was also found, as
described below.) Lastly, household exposure toradon has
been shown to yield a correlation between increased hprt
mutant frequency and total exposure (55).
Exposure to chemical agents such as those in combina-
tion chemotherapy results in an increased frequency of
gpa variants and hprt mutants (56-58). An increase in
hprt variant frequency was found in two studies of the
effects ofexposure to cyclophosphamide, eithertherapeu-
tic or occupational (23,59). Occupational exposure to eth-
ylene oxide resulted in increases in both the Hb variant
and hprt mutant frequency (60,61).
When the studies were able to access the longitudinal
stability ofthe increased variant/mutant frequencies, ele-
vations were generally found to be transient over time.
Thus, the assays appear to be able to detect recent expo-
sures to genotoxic agents. However, the effects of expo-
sures in the more distant past to ionizing irradiation are
also clearly demonstrated. Chronic exposures, as in the
radon study, maybe most relevantforhuman risk assess-
ment, and more studies ofthis type are needed.
Molecular Analyses of in Vivo Somatic
Mutations in Humans
Hprt and HLA mutations arising in vivo in T-lympho-
cytes may be analyzed at the molecular level using tech-
niques such as direct Southern blotting or genomic
polymerase chain reaction (PCR) amplification to define
major structural alterations and the direct PCR ofcDNA
andsequencingtocharacterizepointmutations(62-64). In
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Table 2. Comparative results ofvariant/mutant frequencies for the different in vivo somatic cell gene mutation assays in adult humans
(ionizing radiation effects).
RBC assays T-lymphocyte assays
hprt
Group Hb gpa Short term Cloning
Radiation technicians NT NT NT t (41,42)
Radiation therapy NT - (32) 1 (33) 1 (43,44,53,54)
- (57)
Atomic bomb NT T (45,46) NT T (15,47)
Radiation accidents t (6) T (48,49) T (24,50) NT
Radionuclide NT NT NT 1 (51)
angiography -(52)
Radon (household) NT NT NT 1 (55)
Abbreviations: RBC, red blood cells; Hb, hemoglobin; GPA, glycophorin-A; HPRT, hypoxanthine-guanine phosphoribosyltransferase; NT, nottested;
, variant/mutant frequency increase; -, no change.
aHLA assay not conducted for any group.
Table 3. Comparative results ofvariant/mutant frequencies for the different in vivo somatic cell gene mutation assays in adult humans
(chemical effects).
RBC assays T-lymphocyte assays
hprt
Hb gpa Short term Cloning
Combination chemotherapy NT 1 (56) NT 1 (57,58)
- (44)
Cyclophosphamide NT NT 1 (23,59) NT
Ethylene oxide T (60) NT NT T (61)
Abbreviations: RBC,redblood cells; Hb, hemoglobin; GPA, glycophorin-A; HPRT, hypoxanthine-guanine phosphoribosyltransferase; NT, nottested;
T , variant/mutant frequency increase; -, no change.
'HLA assay not conducted for any group.
adition, studies of TcR gene rearrangement patterns
among mutants from a given individual establish clonal
distributions of in vivo-derived mutants (65).
BackgroundMutations
Approximately 15% of the background in vivo hprt
mutations in adults show gross structural alterations vis-
ible on Southern blots. Most ofthese alterations are dele-
tions. Only the minority, however, are total (i.e., involving
all nine exons of hprt). Breakpoints are apparently ran-
domly distributed throughout the gene with no hot-spots
thus far identified.
The remaining 85% of background in vivo hprt muta-
tions in adults are due to point mutations, i.e., base
changes, frameshifts, splice-site alterations, or small dele-
tions orinsertions,involvinglessthatthe500El) necessary
for detection on Southem blots. A repository is being
maintained byThomas Skopek at the University ofNorth
Carolina at Chapel Hill to collate all data on such hprt
point mutations. This repository nowincludes information
concerning both spontaneous (background) and induced
in vivo and in vitro mutations in human cells. Overall, the
most common point mutations observed at hprt are base
substitutions (85% missense, 13% nonsense, 2% no amino
acid change), followed by splice site mutations, frame-
shifts, and smalldeletions. Everyclass ofbase substitution
has been observed at similar frequencies, and these have
been distributed throughout all nine exons. Splice site
mutations have involved all exons except exon 1. Frame-
shift mutations, in general, occur at or adjacent to
sequences containing two or more consecutive identical
bases, whereas small deletions, involving from 2 to 49 bp,
are often flanked by 2-5 base direct repeat sequences.
ThebackgroundinvivohprtT-cellpointmutationshave
thus far not shown a characteristic pattern or spectrum.
However, several hot-spots have been observed, i.e., sites
atwhich mutation has occurred more than once. Given the
large target size of hprt, the current inability to define a
spontaneous mutational spectrum is not unexpected; the
total number of background in vivo hprt mutations ana-
lyzed to date has simply not been sufficient.
Unexpectedly, the background hprt mutational spec-
trum ofnewbornhumans, determinedfromT-cellmutants
isolated from placental blood and reflecting mutations in
the fetus, is quite different from that determined for
adults. Rather than 15% showing gross structural altera-
tions on Southern blots, up to 85% offetal mutations show
such gross changes (66,67). Furthermore, while adult
breakpoints forgrossalterations arerandomlydistributed
within the hprt gene, fetal mutations have a characteristic
partial deletion that involves only exons 2-3. These muta-
tions have been shown to contain specific breakpoints in
introns 1 and 3, which is consistentwith the known specif-
icity of the VDJ recombinase activity (68). Molecular
analyses of in vivo HLA T-cell mutations are also in
progress. Southern blot studies of background mutants
from nonexposed adults reveal that approximately 30%
result from total gene deletions. Significantly, the use of
chromosome 6p polymorphic DNA probes further shows
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another 30% to be homozygous for markers for which the
individual is constitutionally heterozygous. The most
likelyinterpretation isthatthese invivobackground HLA
mutations result from a process akin to somatic recom-
bination (69,70). If so, HLA becomes an important
recorder for such events. At present, molecular studies of
in vivo HLA mutations are being pursued by a single
group. There are nopublishedmolecularcharacterizations
ofin vivo fetal mutations, or ofthe remaining 30+ % ofin
vivo background mutations in adults that appear to be
point mutations.
InducedMutations
The only molecular mutational spectrum thus far
defined forinduced invivo somaticmutations in humansis
for hprt in individuals following exposures to ionizing
radiation (53,54). The exposed individuals are cancer
patients receiving radioimmunoglobulin therapy (RIT).
RIT involves the intravenous administration of a radi-
onuclide linked to an antibody that localizes to tumor and
other body tissues, thus providing chronic total body
irradiation in an exponentially decaying dose. Two hun-
dred forty-one independent invivo hprtmutational events
occurring in 19 RIT patients, 118 independent in vivo hprt
mutations in four cancer patients before RIT, and 287
background mutations in normal individuals were ana-
lyzed by Southern blots and the results compared. The
mean percent of gross structural alteration mutations in
the radiation-exposed group was 38.3%, compared to
16.9% in cancer patients before RIT and 14.2% in normal
adults. Thus, ionizingradiation resulted in acharacteristic
in vivo hprtmolecular mutational spectrum characterized
by deletions. The spectral change from background is not
producedbythe canceritself, asitdoes notoccurincancer
patients pre-RIT. Further analysis showed the average
size ofhprt deletions tobe increased byionizingradiation.
Forty-one percent of the gross structural alterations in
the radiation associated mutations were total hprt dele-
tions, compared to 22% and 15% in normal adults and pre-
RIT cancerpatients, respectively. Molecular studies using
linked X-chromosome DNA anonymous probes and
pulsed-field gel electrophoresis have shown that some of
the hprt deletions are quite large, i.e., up to 2 Mb (71,72).
Finally, acorrelationwas found between thepercentage of
in vivo hprt mutations in an individual showing a gross
structural alteration and the cumulative radiation dose
received by the individual. In fact, 67% ofthis variability
could be explained bytheionizingradiation exposure. This
study indicates that determining the in vivo hprt molecu-
lar mutational spectrum is valuable in individuals exposed
toionizingradiation, andmaybe asimportant as quantita-
tive mutation studies for this particular genotoxic risk
recognition.
Conclusions
Genetic damage manifest as gene mutations can clearly
be determined in human somatic cells and the mutagenic
effects of exposure to genotoxic agents can be quantified.
The four assays described here provide the ability to
detectacomplete spectrum ofmutagenic effects.The RBC
assays have the potential advantage of long memory
because of the stem-cell component. The T-lymphocyte
assays allow direct molecular characterization of the full
range ofmutation events and the advantage ofproviding a
temporal relationshipbetweenthe exposure and themuta-
tion event.
These biomarkers can clearly provide measurement of
somatic cell mutations occurring in human and the
increases which result from exposure to genotoxic agents.
Future studies will determine the correlation of these
specific somatic cell effectswith human genotoxic diseases
and the utility ofthese assays for risk assessment.
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